US EditionPublished • loading... • Updated
Eli Lilly Teams Up With Two Biotechs To Target Autoimmune Disease, Hearing Loss In Deals Worth $3 Billion - Eli Lilly and Co (NYSE:LLY)
- On Wednesday, Eli Lilly announced an agreement with Germany-based Seamless Therapeutics to develop hearing loss treatments, marking Seamless's first major pharma partnership and expanding Lilly's hearing loss pipeline.
- Seamless's leaders say talks that began in or before 2024 prompted Lilly to approach Seamless about its recombinase technology, reflecting Lilly's recent investments including the $700 million Institute for Genetic Medicine.
- Seamless's platform uses recombinases that cut and rejoin DNA directly, enabling large, precise insertions independent of cellular repair, with enzyme discovery shortened to six months via directed evolution in bacteria.
- Under the deal, Seamless Therapeutics will design site-specific recombinases and grant Eli Lilly an exclusive license while the latter advances candidates through development and commercialization, with Seamless eligible for more than $1.12 billion in payments excluding royalties.
- Lilly's existing AK-OTOF program complements a competitive field including Regeneron and Sensorion, while Seamless Therapeutics aims to identify its first development candidate in 2026 and expand Lexington, MA offices.
Insights by Ground AI
14 Articles
14 Articles
Eli Lilly Teams Up With Two Biotechs To Target Autoimmune Disease, Hearing Loss In Deals Worth $3 Billion - Eli Lilly and Co (NYSE:LLY)
Repertoire Immune Medicines entered a strategic collaboration on Thursday with Eli Lilly and Co. (NYSE:LLY) to develop tolerizing therapies for multiple autoimmune diseases. • Eli Lilly and Co stock is showing positive momentum. Where are LLY shares going? Repertoire Immune is a biotechnology company focused on the discovery and development of programmable T cell-targeted immune medicines. Under the terms of the agreement, Repertoire will receiv…
·New York, United States
Read Full Article
Lilly signs up to $1.93 billion deal with Repertoire for autoimmune therapies
Drugmaker Eli Lilly is partnering with Repertoire Immune Medicines in a deal worth up to $1.93 billion to develop therapies for multiple autoimmune diseases, the Massachusetts-based biotech said on Thursday.
·United Kingdom
Read Full Article
Coverage Details
Total News Sources14
Leaning Left0Leaning Right1Center7Last UpdatedBias Distribution88% Center
Bias Distribution
- 88% of the sources are Center
88% Center
C 88%
12%
Factuality
To view factuality data please Upgrade to Premium
